Acadian Asset Management
OREX

Acadian Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Acadian Asset Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-79,214
Closed -$1.36M – 1636
2015
Q4 		$1.36M Buy
79,214
+75,241
+1,894% +$1.79M 0.01% 641
2015
Q3 		$83K Buy
+3,973
New +$136K ﹤0.01% 1010

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management's OREX Position: Q1 2016 in Review

Acadian Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 79,214 shares — an estimated $1.36M sold.

Acadian Asset Management first reported a position in OREX in Q3 2015 and held it in 2 quarters. The position peaked at $1.36M in Q4 2015. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • Acadian Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Acadian Asset Management sold 79,214 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $1.36M.
  • Acadian Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
  • Acadian Asset Management's Orexigen Therapeutics, Inc. position peaked at $1.36M in Q4 2015.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Acadian Asset Management's 13F filing for Q1 2016, filed 14 Apr 2016.